You are here

Article Text

Article menu
Download PDFPDF
PostScript
Featured correspondence
Propafenone contraindicated in the elderly?
  1. Charles J H J Kirchhof1,
  2. H J G M Crijns2,
  3. I C van Gelder2
  1. 1Department of Cardiology, Rijnland Hospital, Leiderdorp, The Netherlands
  2. 2Academic Hospital Maastricht, Maastricht, The Netherlands
  1. Correspondence to Charles JHJ Kirchhof, Department of Cardiology, Rijnland Hospital, Leiderdorp, The Netherlands; ch.kirchhof{at}orange.nl

https://doi.org/10.1136/hrt.2010.217596

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    To the Editor With great interest we read the paper by Alboni et al.1 The investigators studied intravenous class Ic antiarrhythmic drug (AAD) administration (propafenone and flecainide) as a predictor for adverse effects when used in a ‘pill-in-the-pocket’ regimen (PITP).

    Alboni and colleagues suggest that intravenous administration of flecainide or propafenone for pharmacological conversion of atrial fibrillation to sinus rhythm cannot predict the occurrence of adverse effects when these agents are subsequently …

    View Full Text

    Footnotes

    • Linked articles 217604.

    • Competing interests None.

    • Provenance and peer review Not commissioned; not externally peer reviewed.

    Linked Articles

    • PostScript
      Paolo Alboni
      Heart 2010; 97 262-262 Published Online First: 28 Dec 2010. doi: 10.1136/hrt.2010.217604